Cutaneous reactions following COVID-19 vaccination have been frequently described, whereas larger case series by dermatologists are lacking. This study assesses SARS-CoV-2 vaccination-associated skin reactions, severity, treatment, course, eliciting vaccines, allergy test results and tolerance to revaccination. Single-institutional, non-interventional study of dermatologists assessing cutaneous manifestations in 83 patients in Germany. 93 reactions were presented. Manifestations clustered into immediate (n=51, 54.8%) and delayed hypersensitivity reactions (n=10, 10.8%), chronic inflammatory skin diseases (n=13, 14.0%), reactivation of latent herpes virus infection (pityriasis rosea/herpes zoster; n=9; 9.7%) and others (n=10, 10.8%). Vaccination was associated with new (76.3%) - mostly hypersensitivity reactions - or exacerbation of known skin diseases (23.7%), in this case predominantly chronic inflammatory skin diseases. Reactions occurred primarily within the first week (72.8%) and after first vaccination (62.0%). Treatment was required in 83.9% and hospitalization in 19.4%. In 48.8% revaccination led to recurrence of the same reactions. Disease was ongoing at last consultation in 22.6%, primarily in chronic inflammatory skin diseases. Allergy tests were performed in 15 patients (18.1%) and resulted negative. It can be assumed that vaccination may trigger immune activation-related reactions especially in those patients predisposed to develop respective skin diseases.